Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-DEP regimen for children with chronic active Epstein-Barr virus infection
ChiCTR1900020574Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegaspargase, pegylated liposomal doxorubicin, etoposide and methylprednisolone in chronic active Epstein-Barr virus infection (CAEBV), sponsored by Beijing Children's Hospital. Primary endpoints: blood routine examination, glutamic-pyruvic transaminase and 10 more. Started Jan 2019; status: recruiting.
02
Drugs
pegaspargasepegylated liposomal doxorubicinetoposidemethylprednisolone
03
Conditions
chronic active Epstein-Barr virus infection (CAEBV)
Beyond the preview
Go deeper on ChiCTR1900020574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020574.